Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for PH

 Actelion Launches Increased Strength Formulation of Ventavis (Iloprost) for

Pulmonary Arterial Hypertension in the United States

SOUTH SAN FRANCISCO, Calif., Sept. 1 /PRNewswire/ -- Actelion Pharmaceuticals
US, Inc., today announced the first commercial sales of a new 20 microgram per
milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York
Heart Association Class III and IV pulmonary arterial hypertension (PAH). This
increased strength formulation delivers the same dose of Ventavis in half the
volume, which is expected to reduce inhalation time and further support
patient compliance. The 20 mcg/mL formulation of Ventavis(R) is available
immediately for pre-order, and fulfillment of initial prescriptions by
specialty pharmacies is anticipated beginning the week of September 14.

Link To Article